Page 73 - Sohini Das

Decoded: How WHO's mRNA Tech Transfer Hub is working for vaccine access

After examining several proposals from India, Hyderabad-based Biological E has now been selected to partner with WHO to make mRNA technology-based vaccines in the country

After 715 days, India reports less than 1,000 daily fresh Covid-19 cases

Experts think that daily cases are unlikely to spike, leading to a 'wave', in the short term, and that the pandemic appears to be over.

Biological E recipient of mRNA tech as part of WHO's tech transfer hub

WHO and partners to work with Indian govt and the firm to develop roadmap and put in place training and support for Biological E to start producing mRNA vaccines at the earliest

SII, Bharat Biotech halt production of Covid vaccines as demand slips

High inventory, lack of fresh orders behind the decision; focus on non-Covid vax

No issue with Covaxin certificate: Bharat Biotech on WHO suspending vaccine

Bharat biotech says there are no issues with Covaxin or its certification, further we will focus on pending facility maintenance, has no supply commitments pending for UN agency.

KKR-backed JB Chemicals bets big on lozenges and probiotic products

JB Chemicals now plan to enter new areas like sleep disorders, sexual wellness, motion sickness, and immunity apart, from the conventional areas like cough, sore throat, etc.

US lawsuit may not impact India launch of Gennova's mRNA vaccine

The vaccine is now under review by the regulator, and if approved, it may be ready for launch in the Indian market and will be the first mRNA Covid vaccine to be available here.

Bharat Biotech slows down Covaxin production as it sees decrease in demand

'For the coming period, the company will focus on pending facility maintenance, process and facility optimization activities,' the Hyderabad-based company said

Lupin's New Jersey facility gets 13 US FDA observations

The observations do not, however, imply any restriction on supplies

Bulk of pharma growth came from price hikes, shows data

The average increase in prices was 3.1 per cent in the past five years.

Demand for chronic drugs likely to rise 30% ahead of price hike

There would be a general rise in demand for chronic medicines as consumers would stock up ahead of a price rise

States begin doing away with Covid restrictions; Delhi removes no-mask fine

Some states like Tamil Nadu are, however, taking a cautious approach, and are yet to announce major relaxations

Data shows India's changing Covid-19 mix as share of omicron samples dips

Govt stopped updating weekly numbers on genetic sequencing in January

Vaccine policy group seeks more lab data on tests for mixing Covid doses

NTAGI has a month to go before it gives its advice to the government on inoculation strategy.

Pharma SMEs stock up on a month's raw material amid supply disruptions

The lockdown in various Chinese provinces, including Shanghai, is likely to delay shipments by two weeks to a month, said domestic players.

Indian home healthcare market to grow 2.5x to $19.9 bn by 2025: Nathealth

The study estimated that the market has a potential to grow an additional $5 bn with the right impetus

Alembic acquires 100% stake in Aleor Dermaceuticals from JV partner

The move is aimed at strengthening its skin-related manufacturing and marketing footprint

Aurobindo's Veritaz acquisition unlikely to add much value: Analysts

Deal is nonetheless a stepping stone in the drug firm's strategic plan to focus on domestic formulations market, where it aims to have Rs 1,000-cr sales in three years

Aurobindo Pharma acquires Veritaz' domestic business for Rs 171 cr

Move marks Aurobindo's increasing focus on Indian market

Alembic Pharma targets 10-12 product filings from Karkhadi facility

Resolution of the observations made by the USFDA (for which Alembic has already responded to the regulator) is critical for Alembic's US business